Evoke Pharma Files 8-K: Other Event Reported
| Field | Detail |
|---|---|
| Company | Evoke Pharma Inc |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-event
Related Tickers: EVOK
TL;DR
Evoke Pharma (EVOK) filed an 8-K for an 'Other Event' on Aug 6. Details TBD.
AI Summary
Evoke Pharma, Inc. filed an 8-K on August 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms the company's identity, its principal executive offices at 420 Stevens Avenue, Suite 230, Solana Beach, California, and its telephone number.
Why It Matters
This filing indicates a material event has occurred for Evoke Pharma, Inc., requiring public disclosure, though the specific nature of the event is not detailed in this document.
Risk Assessment
Risk Level: medium — The filing is an 8-K for an 'Other Event,' which could be significant, but the lack of detail makes it difficult to assess the immediate risk.
Key Players & Entities
- Evoke Pharma, Inc. (company) — Registrant
- August 06, 2025 (date) — Date of Report
- 420 Stevens Avenue, Suite 230, Solana Beach, California (location) — Principal Executive Offices
- 858 345-1494 (phone_number) — Registrant's Telephone Number
FAQ
What specific event is Evoke Pharma, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event.
When was this 8-K filing submitted?
The filing was submitted on August 6, 2025.
Where are Evoke Pharma, Inc.'s principal executive offices located?
The principal executive offices are located at 420 Stevens Avenue, Suite 230, Solana Beach, California.
What is the Commission File Number for Evoke Pharma, Inc.?
The Commission File Number for Evoke Pharma, Inc. is 001-36075.
What is the IRS Employer Identification Number for Evoke Pharma, Inc.?
The IRS Employer Identification Number for Evoke Pharma, Inc. is 20-8447886.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Evoke Pharma Inc.